Sjogren-Larsson Syndrome

In an interview with Benzinga, Aldeyra Therapeutics (NASDAQ: ALDX) CEO Dr. Todd Brady discussed his company’s opportunities. “What we have is an aldehyde trap,” began Brady. “We developed molecules that bind to and dispose of aldehyde.” Aldehydes are an agent in...